Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Debate 42A Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 42B Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 43A Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 43B Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 44A What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 44B What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 45A Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 45B Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 46A What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 46B What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 47A Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Debate 47B Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Debate 47B - Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
No
from Section V - Cervical Cancer
Published online by Cambridge University Press: 20 July 2023
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Debate 42A Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 42B Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 43A Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 43B Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 44A What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 44B What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 45A Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 45B Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 46A What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 46B What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 47A Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Debate 47B Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Summary
Cervical cancer is the fourth most commonly diagnosed and one of the deadliest cancers in women worldwide. There is an urgent need for more active treatments and rationally designed targeted therapies for advanced disease. Recently, immunotherapy has been proven to be effective in several solid tumors. There are few phase I/II studies in advanced or recurrent cervical cancer patients, no quality of life analysis in the studies, limited objective responses, and no clear superiority over second-line chemotherapy, but certainly more expense. Therefore, currently there is no role of immunotherapy in treatment of cervical cancer.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 288 - 290Publisher: Cambridge University PressPrint publication year: 2023
References
Lheureux, S, et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus–related cervical carcinoma. JAMA Oncol 2018;4(7):e173776.CrossRefGoogle ScholarPubMed
Chung, HC, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37(17):1470–1478.CrossRefGoogle ScholarPubMed
Frenel, J-S, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 Trial. J Clin Oncol 2017;35(36):4035–4041.CrossRefGoogle ScholarPubMed
Boussios, S, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review. Crit Rev Oncol/Hematol 2016;108:164–174.CrossRefGoogle ScholarPubMed
Naumann, RW, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 Trial. J Clin Oncol 2019;37(31):2825–2834.CrossRefGoogle ScholarPubMed
Naumann, RW, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with recurrent /metastatic cervical cancer: results from Checkmate 358. Ann Oncol 2019;30 (Suppl. 5):v851–v934.CrossRefGoogle Scholar